To test whether asparaginase could directly antagonise tumour growth, we added E. coli-derived asparaginase to tumours and measured growth by MTT, showing a dose-dependent halting of tumour metabolism (Fig. 8H), indicating that intestinal tumour organoids are sensitive to asparagine depletion. The gene discussed is ASPG; the disease is neoplasm.